Teratogenicity Study of D-Allulose: NOAEL and Food-Use Safety Context

Allulose Safety: What the Developmental Study Shows

A prenatal developmental toxicity study in rats found no treatment-related developmental abnormalities at allulose doses up to 5,000 mg/kg/day — a NOAEL (No-Observed-Adverse-Effect-Level) of 5,000 mg/kg/day in this model.

Published in Toxicology Reports, the study is one piece of the safety dossier behind allulose's food-use status. It also answers a question that comes up often: is allulose safe during pregnancy?

Why Developmental Toxicity Studies Exist

Teratogenicity studies are standard safety assessments that test whether a substance causes birth defects when given during pregnancy. They are part of the toxicology package required for any food ingredient or food additive.

Allulose is consumed by the general population, including pregnant women, so a developmental toxicity study is essential to its safety evaluation.

The Study Design

• Model: Pregnant Sprague-Dawley rats
• Design: OECD 414-style prenatal developmental toxicity study
• Exposure: Oral administration during gestation days 6-15
• Dose levels: Up to 5,000 mg/kg/day

This is the standard regulatory design for evaluating developmental toxicity.

The Key Result: NOAEL of 5,000 mg/kg/day

The study reported no treatment-related developmental abnormalities at any dose tested. The NOAEL was 5,000 mg/kg/day — the highest dose given.

Putting 5,000 mg/kg/day in Perspective

For a 70kg person:

• 5,000 mg/kg/day × 70 kg = 350 grams per day
• No effects were seen at this level in rats
• Realistic human consumption: 10-30 g/day
• Typical serving: 5-15 g

The NOAEL is more than 10x higher than even the highest realistic human intake — a wide safety margin.

Comparison	Amount
Study NOAEL (rat)	5,000 mg/kg/day
Human equivalent (70kg)	~350 g/day
Realistic human intake	10-30 g/day
Typical serving	5-15 g

How to Frame This Correctly

This study is strong toxicology evidence, but it needs careful interpretation:

• It is animal toxicology data, not a guarantee about every human consumer
• It is one component of the safety dossier (alongside human tolerance, mutagenicity, and other studies)
• It supports the evaluated food-use safety of allulose — it does not claim "zero risk for everyone"
• Regulatory decisions also depend on market-specific approvals (US GRAS, other markets)

What This Means for the Industry

For ingredient buyers, product developers, and regulatory teams, toxicology studies like this support:

Use	Purpose
Internal regulatory dossiers	Evidence of developmental safety
Customer documentation	Safety data for B2B buyers
Risk assessments	Serving-size and exposure analysis
Consumer confidence	Backs "allulose is safe" communications

Frequently Asked Questions

Q: Is allulose safe during pregnancy? This study found no developmental abnormalities at doses up to 5,000 mg/kg/day in rats. As with any ingredient, pregnant women should follow label guidance and consult healthcare professionals. This toxicology data supports the safety evaluation but is not medical advice.

Q: What does NOAEL mean? No-Observed-Adverse-Effect-Level — the highest dose at which no adverse effects were seen. Here, it is 5,000 mg/kg/day.

Q: Is allulose approved as safe? In the US, allulose has GRAS (Generally Recognized As Safe) status. Regulatory status varies by market; this toxicology data supports those evaluations.

Wrap-Up

The developmental study establishes a NOAEL of 5,000 mg/kg/day with no observed abnormalities — a wide margin over realistic human intake. It is a key data point in allulose's safety dossier, best framed as "toxicology supports evaluated food-use safety" rather than "zero risk for everyone."

Read the full paper: PubMed